» Common asthma drug shows promise for reversing fatty liver
12/05/26 08:00 from Breaking World Pharma News
MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide. It is also a leading cause of liver transplantation, yet treatment options remain limited....
» Nanoparticles overcome drug-resistant cancer via sequential drug release and photothermal therapy
11/05/26 08:00 from Breaking World Pharma News
Cancer cells frequently develop the ability to expel anticancer drugs before they can work - a phenomenon called multidrug resistance (MDR) - which is one of the leading reasons why chemotherapy fails in patients. This research addresses...
» AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors
08/05/26 08:00 from Breaking World Pharma News
Published in Science Advances, St. Jude Children’s Research Hospital scientists used a mix of genetic cancer dependency data, artificial intelligence (AI) and naturally occurring mutations to prioritize safer cancer drug targets. They fo...
» Researchers identify natural compound that disarms drug-resistant bacteria
07/05/26 08:00 from Breaking World Pharma News
Every year, antibiotic-resistant Staphylococcus aureus, commonly known as “staph,” causes serious infections and outbreaks in hospitals and community settings, disproportionately affecting vulnerable populations, including the elderly an...
» Scientists discover a new way to make drug-resistant cancer treatable again
06/05/26 08:00 from Breaking World Pharma News
Cancer cells survive by repairing damage to their DNA - even damage that would normally be fatal. One of their most important defense systems is homologous recombination, a high-precision repair pathway that fixes broken DNA using key pr...
» A new drug concept to treat obesity and type 2 diabetes
05/05/26 08:00 from Breaking World Pharma News
A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signalling pathway as a “door opener” and ...